Increased reactivity to chemical but not to heat noxious stimuli in mice producing anti-idiotypic antibodies for substance P

Calvino, Bernard; Couraud, Jean-Yves; Maillet, S.; Pradelles, Philippe; Besson, Jean‐Marie

doi:10.1016/0006-8993(88)90388-5

Cited by 11 publications

(4 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Mice were bled at the end of the experiments and all sera were tested for anti-Id content. As previously reported (Calvino et al, 1988), a significant correlation (p < 0.01) was found between the licking times during the early response and the corresponding anti-Id serum concentrations.…”

Section: Fig 4_supporting

confidence: 70%

“…Finally, in order to determine whether anti-Id abs could exert any physiological effect in vivo, which is of course a prerequisite for potential use of these abs in clinical studies, experimentation was conducted to determine whether the anti-Id abs produced by an animal could affect its sensitivity to pain (Calvino et al, 1988). Anti-SP mouse monoclonal abs were injected into other mice of the same strain, which produced anti-Id abs (Ab2 mice), while unrelated monoclonal abs were injected into control mice.…”

Section: In Vivomentioning

confidence: 99%

See 1 more Smart Citation

Use of anti-idiotypic antibodies as probes for in vitro and in vivo identification of substance P receptor

Couraud

Maillet

Conrath

et al. 1990

Molecular and Chemical Neuropathology

Self Cite

View full text Add to dashboard Cite

In order to develop immunological tools for studying the receptor of the neuropeptide substance P (SP), anti-idiotypic antibodies (anti-Id abs) were produced by immunization with anti-SP antibodies whose specificity was close to that of the SP receptor. Immunological studies revealed structural similarity between some anti-Id abs and SP itself. As a consequence, these anti-Id abs were able to bind to mammalian SP receptors. These antibodies were used in immunocytochemistry to label SP receptors both in the rat spinal cord and in rat and guinea pig peripheral tissues (parotid gland and trachea, respectively). Like SP, anti-Id abs were able to trigger protein secretion by isolated rat parotid gland cells. Finally, it was shown that anti-Id abs in vivo modulated reactivity to chemical stimuli. These antibodies therefore appear to be promising tools for further biochemical, cytochemical, and pharmacological characterization of SP receptors.

show abstract

Section: Fig 4_supporting

confidence: 70%

Section: In Vivomentioning

confidence: 99%

Use of anti-idiotypic antibodies as probes for in vitro and in vivo identification of substance P receptor

Couraud

Maillet

Conrath

et al. 1990

Molecular and Chemical Neuropathology

Self Cite

View full text Add to dashboard Cite

show abstract

“…In rats, other behaviors, such as flinching or jerking of the injected paws, have also been quantified; but scoring these common behavioral responses becomes more difficult in mice, due to rapid movements in these animals. Again, scoring of the time spent licking, or licking and biting, the injected paw is the most common method of behavioral assessment in mice [86].…”

Section: Intradermal Injectionsmentioning

confidence: 99%

Common animal models for spasticity and pain

Eaton¹

2003

JRRD

View full text Add to dashboard Cite

Abstract-Animal models of spasticity and pain have allowed for the elucidation of possible mechanisms and the evaluation of potential therapeutic interventions for these serious clinical problems. Each model mirrors the clinical appearance of many features of the syndrome, but few reproduce the myriad patient reports of either intensity or relevant contributing factors, especially in models of chronic neuropathic pain. Often these models have been used to predict the potency and efficacy of pharmacologic agents that work in human pain states. Pain models have relied on measurements of the shifts in behavioral hypersensitivity to tactile and thermal stimuli, tests that are not used quantitatively in human patients. Even with the multiple peripheral and central models of spasticity and pain used in animals, only a few actually test human conditions: namely, diabetic neuropathy, chemotherapy, and immunotherapy for tumors. However, all these models have allowed for the comparison of certain behavioral, cellular, biochemical, and molecular mechanisms with human patient populations. Here we review the few extant models of spasticity, nerve injury, and central injury models of pain, and describe their features and use.

show abstract

“…These polyclonal antibodies share with SP some binding and pharmacological properties ; i .e ., they recognize the SP receptor in biochemical and immunocytochemical studies in mammalian nervous and nonnervous structures (Conrath et al ., 1988 ;Kümmer et al ., 1990 ;Fischer et al ., 1992) . They also display pharmacological properties, behaving as agonists or antagonists of SP, both in vitro and in vivo (Calvino et al ., 1988 ;Maillet et al ., 1990) . We have now investigated whether antireceptor antibodies of predefined specificity, i .e ., also recognizing the SPbinding domain on the SP receptor, can be obtained by an alternative immunological method, originally developed by Blalock and coworkers (Bost et al ., 1987 ;Bost and Blalock, 1989), which consists of immunizing with synthetic peptides derived from the sequence of RNA complementary to the mRNA coding for the receptor ligand .…”

mentioning

confidence: 99%

Antipeptide Polyclonal Antibodies that Recognize a Substance P‐Binding Site in Mammalian Tissues: A Biochemical and Immunocytochemical Study

Bret-Dibat¹,

Zouaoui

Déry³

et al. 1994

Journal of Neurochemistry

Self Cite

View full text Add to dashboard Cite

We used complementary peptide methodology to obtain antibodies against the receptor for the neuropeptide substance P, specifically directed at the ligand‐binding domain. Rabbits were immunized with two distinct peptides derived from the sequence of the RNA complementary to the mRNA for substance P. Binding experiments revealed that antipeptide polyclonal antibodies were able to recognize, through their paratope, a specific binding site on the rat parotid cell membranes. Substance P and antibodies competed for this binding site, because preincubation of membranes in the presence of substance P significantly reduced antibody binding, and conversely, preincubation of membranes in the presence of antibodies partly inhibited the binding of radioiodinated substance P. Immunocytochemical experiments performed on the rat cervical spinal cord show that the distribution of labeling by antibodies is similar to that observed by conventional autoradiography using 125I‐substance P. Here again, control experiments demonstrated that antibodies and substance P were competing for the same binding site on the spinal cord. These biochemical and immunocytochemical data indicate that antipeptide antibodies recognize a substance P membrane binding site in nervous and nonnervous mammalian tissues. This site is likely to correspond to the NK1 specific receptor for substance P.

show abstract

Increased reactivity to chemical but not to heat noxious stimuli in mice producing anti-idiotypic antibodies for substance P

Cited by 11 publications

References 14 publications

Use of anti-idiotypic antibodies as probes for in vitro and in vivo identification of substance P receptor

Use of anti-idiotypic antibodies as probes for in vitro and in vivo identification of substance P receptor

Common animal models for spasticity and pain

Antipeptide Polyclonal Antibodies that Recognize a Substance P‐Binding Site in Mammalian Tissues: A Biochemical and Immunocytochemical Study

Contact Info

Product

Resources

About